@George1972
Awesome find.
The "cancer" story of ATL1102 is yet to begin - that will really get the market interested.
________________
"The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d...."
.
Where others have failed will Atl1102 succeed ?, page-703
-
- There are more pages in this discussion • 394 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
